logo
  

Pfizer Reaches Deal With Acuitas For Lipid Nanoparticle Delivery System For Use In MRNA Vaccines

Pfizer (PFE) said that it has entered into an agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics.

The agreement expands Pfizer's access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer's mRNA strategy.

Acuitas' clinically-validated LNP technology is used in COMIRNATY, the Pfizer-BioNTech COVID-19 vaccine.

As per the deal, Pfizer will have the option to license, on a non-exclusive basis, Acuitas' LNP technology for up to 10 targets for vaccine or therapeutic development.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lyons Magnus LLC has expanded its initial recall of nutritional and beverage products to include additional brands and code dates, the U.S. Food and Drug Administration announced. The products were recalled due to the potential for microbial contamination, including from the organisms Cronobacter sakazakii and Clostridium botulinum. Tesla Inc. founder and CEO Elon Musk has sold some of his stake in the luxury electric car maker to avoid an emergency sale of its stock in the event of a forceful Twitter deal. Twitter Inc. and Tesla shares were gaining more than 4 percent in the pre-market activity on the NYSE and Nasdaq, respectively, following the news. Meta Platforms Inc., the parent of Facebook, Instagram, and WhatsApp, has added three more new privacy features to WhatsApp in its bid to enhance control and privacy on the popular messaging app. These features will give the user more control over their messages with added interlocking layers of protection.
Follow RTT